The Orlistat Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Orlistat Market:
https://www.thebusinessresearchcompany.com/report/orlistat-global-market-report
According to The Business Research Company’s Orlistat Global Market Report 2024, The orlistat market size has grown strongly in recent years. It will grow from $2.85 billion in 2023 to $3.03 billion in 2024 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to growing awareness of obesity-related health risks, regulatory approvals for orlistat as a prescription medication, the availability of orlistat in lower doses over-the-counter, physician recommendations, and increasing costs of obesity-related healthcare.
The orlistat market size is expected to see strong growth in the next few years. It will grow to $3.91 billion in 2028 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to increasing healthcare spending on obesity treatments, sedentary lifestyles along with unhealthy eating habits, government programs promoting weight loss and healthy living, the aging population, and prescriptions to over-the-counter shift. Major trends in the forecast period include AI-driven diet plans, telehealth services, automated devices that remind patients to take their medication and track adherence, virtual reality workouts, and digital therapeutics.
Increasing obesity rates are expected to propel the growth of the orlistat market going forward. Obesity is a medical condition characterized by excessive body fat accumulation, which can negatively impact health. It is commonly measured by a body mass index (BMI) of 30 or higher. Obesity is increasing due to factors such as poor diet, lack of physical activity, and sedentary lifestyles. Orlistat is used in obesity management by inhibiting the absorption of dietary fats, which helps reduce body weight and maintain weight loss. It is often prescribed alongside a reduced-calorie diet and exercise for more effective results. For instance, in March 2022, according to the World Health Organization (WHO), a Switzerland-based intergovernmental organization, over 1 billion individuals globally were affected by obesity, comprising 650 million adults, 340 million adolescents, and 39 million children. This figure continues to rise, and it is projected that by 2025, around 167 million people, including both adults and children, will experience deteriorating health due to being overweight or obese. Therefore, increasing obesity rates are driving the growth of the orlistat market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=18422&type=smp
The orlistat market covered in this report is segmented –
1) By Type: 120 Milligram (Mg), 60 Milligram(Mg)
2) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
3) By Application: Weight-Reducing Aid, Other Applications
Major companies operating in the orlistat market are developing innovative products, such as weight loss drugs, to enhance personal hygiene and comfort through advanced technology and design. A weight loss drug refers to a medication designed to help individuals reduce body weight by suppressing appetite, increasing metabolism, or blocking fat absorption. For instance, in November 2023, Eli Lilly and Company, a US-based pharmaceutical company, received US Food and Drug Administration (FDA) approval for Zepbound (tirzepatide) injection, a new weight loss drug. It is the first and only approved treatment that activates two incretin hormone receptors, GIP and GLP-1, addressing an underlying cause of excess weight. Zepbound is indicated for use as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related condition.
The orlistat market report table of contents includes:
1. Executive Summary
2. Orlistat Market Characteristics
3. Orlistat Market Trends And Strategies
4. Orlistat Market – Macro Economic Scenario
5. Global Orlistat Market Size and Growth
.
.
.
32. Global Orlistat Market Competitive Benchmarking
33. Global Orlistat Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Orlistat Market
35. Orlistat Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
